UGN-102
Showing 1 - 25 of 426
Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder Trial in United States (UGN-102)
Active, not recruiting
- Bladder Cancer
- +2 more
- UGN-102
-
Homewood, Alabama
- +4 more
Dec 15, 2022
Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder Trial in Worldwide (UGN-102)
Recruiting
- Bladder Cancer
- +2 more
- UGN-102
-
Tucson, Arizona
- +76 more
Jul 13, 2022
Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder Trial in Worldwide (UGN-102, TURBT)
Active, not recruiting
- Bladder Cancer
- +2 more
- UGN-102
- TURBT
-
Tucson, Arizona
- +138 more
Nov 15, 2021
Rectal Cancer Trial (Trifluridine/Tipiracil, intensity-modulated radiotherapy)
Not yet recruiting
- Rectal Cancer
- Trifluridine/Tipiracil
- intensity-modulated radiotherapy
- (no location specified)
Jul 27, 2023
Diabetic Foot Infection Trial (TP-102, Placebo)
Not yet recruiting
- Diabetic Foot Infection
- TP-102
- Placebo
- (no location specified)
Jul 6, 2023
Trifluridine/Tipiracil Plus Bevacizumab Versus
Completed
- Metastatic Colorectal Adenocarcinoma
-
Changsha, Hunan, ChinaHunan Cancer hospital
May 11, 2023
Diabetic Gastroparesis Trial in United States (CIN-102 Dose 1, CIN-102 Dose 2, Placebo)
Recruiting
- Diabetic Gastroparesis
- CIN-102 Dose 1
- +2 more
-
Tucson, Arizona
- +19 more
Apr 14, 2023
Rectal Adenocarcinoma, Recurrent Rectal Carcinoma, Stage IV Rectal Cancer AJCC v7 Trial in Scottsdale, Rochester (other,
Completed
- Rectal Adenocarcinoma
- +4 more
- Quality-of-Life Assessment
- +2 more
-
Scottsdale, Arizona
- +1 more
Jan 3, 2023
Cholangiocarcinoma, Stage III Gallbladder Cancer AJCC v7, Stage IIIA Gallbladder Cancer AJCC v7 Trial in Scottsdale, Rochester
Active, not recruiting
- Cholangiocarcinoma
- +6 more
- Laboratory Biomarker Analysis
- Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102
-
Scottsdale, Arizona
- +1 more
Jan 4, 2023
Colon Cancer, Rectal Cancer Trial in United States (TAS-102, oxaliplatin, irinotecan with bevacizumab)
Not yet recruiting
- Colon Cancer
- Rectal Cancer
- TAS-102, oxaliplatin, irinotecan with bevacizumab
-
Elizabeth, New Jersey
- +6 more
Apr 7, 2023
Conjunctivitis, Allergic Trial in United States (ADX-102 Ophthalmic Drops (0.5%), ADX-102 Ophthalmic Drops (0.1%), Vehicle of
Completed
- Conjunctivitis, Allergic
- ADX-102 Ophthalmic Drops (0.5%)
- +2 more
-
Morrow, Georgia
- +4 more
Dec 14, 2022
Kidney Diseases, Kidney Injury, Kidney Failure Trial in Suzhou, Xuzhou (MB-102 DMID, MB-102 OMID, MediBeacon Transdermal
Recruiting
- Kidney Diseases
- +2 more
- MB-102 DMID
- +2 more
-
Suzhou, Jiangsu, China
- +1 more
Jul 11, 2023
Kidney Diseases, Kidney Injury, Kidney Failure Trial in Chicago, San Antonio (MB-102, MediBeacon Transdermal Glomerular
Recruiting
- Kidney Diseases
- +2 more
- MB-102
- MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)
-
Chicago, Illinois
- +1 more
Mar 22, 2023
Colorectal Adenocarcinoma, Gastric Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma Trial in Atlanta (Nanoliposomal
Recruiting
- Colorectal Adenocarcinoma
- +13 more
- Nanoliposomal Irinotecan
- Trifluridine and Tipiracil Hydrochloride
-
Atlanta, Georgia
- +2 more
Jan 6, 2023
Fruquintinib With PD-1 Inhibitors Versus TAS-102 With
Completed
- Metastatic Colorectal Adenocarcinoma
- Fruquintinib
- +3 more
-
Changsha, Hunan, ChinaHunan Cancer hospital
Sep 2, 2023
Gastric Cancer, Pancreatic Cancer Trial in Fukuoka-shi (Phase I part, Phase II part)
Recruiting
- Gastric Cancer
- Pancreatic Cancer
- Phase I part
- Phase II part
-
Fukuoka-shi, Fukuoka, Fukuoka, JapanKyushu University Hospital
Jun 24, 2022
Metastatic Gastric Adenocarcinoma, Second Line, Chemo Trial (nal-IRI /Experimental, Ramucirumab /Experimental,
Not yet recruiting
- Metastatic Gastric Adenocarcinoma
- +2 more
- nal-IRI /Experimental
- +2 more
- (no location specified)
Jun 25, 2023
Delayed Pregnancy Loss, Early Pregnancy Loss Trial (CCT-102 A and CCT-102 B)
Not yet recruiting
- Delayed Pregnancy Loss, Early Pregnancy Loss
- CCT-102 A and CCT-102 B
- (no location specified)
Nov 2, 2023
Refractory/Relapse Neuroblastoma, Pediatric Solid Tumors With Lung Metastases Trial in Fukuoka (Biological)
Recruiting
- Refractory/Relapse Neuroblastoma
- Pediatric Solid Tumors With Lung Metastases
- Biological
-
Fukuoka, JapanKyushu University Hospital
Nov 7, 2022
Colorectal Cancer Trial in Tai'an (Tas-102(Suyuan) combined with bevacizumab)
Not yet recruiting
- Colorectal Cancer
- Tas-102(Suyuan) combined with bevacizumab
-
Tai'an, Shandong, ChinaThe Second Affiliated Hospital of Shandong First Medical Univers
Oct 14, 2023